Publications by authors named "Shari Feinberg"
Background: The Children's Oncology Group defines intermediate-risk rhabdomyosarcoma as unresected FOXO1 fusion-negative disease arising at an unfavourable site or non-metastatic FOXO1 fusion-positive disease. Temsirolimus in combination with chemotherapy has shown promising activity in patients with relapsed or refractory rhabdomyosarcoma. We aimed to compare event-free survival in patients with intermediate-risk rhabdomyosarcoma treated with vincristine, actinomycin, and cyclophosphamide alternating with vincristine and irinotecan (VAC/VI) combined with temsirolimus followed by maintenance therapy versus VAC/VI alone with maintenance therapy.
View Article and Find Full Text PDFArticle Synopsis
- Pediatric oncology patients on active chemotherapy may be at increased risk for severe COVID-19, but the study found that most had mild symptoms, with 73 out of 98 positive cases being symptomatic.
- Severe cases predominantly involved males and obese individuals, with a notable occurrence of persistent lymphopenia; however, the overall mortality rate was low, and no death was solely due to COVID-19.
- Significant delays in cancer treatment were reported, including 67% of SARS-CoV-2 positive patients experiencing interruptions in therapy, highlighting the pandemic's substantial impact on pediatric cancer care.